المؤلفون: Simou,Olympia, Sidiropoulou,Sophia, Koutelekos,Ioannis, Dousis,Evangelos, Toulia,Georgia, Zartaloudi,Aphrodite, Govina, Ourania

المصدر: Perioperative Nursing (GORNA), E-ISSN:2241-3634 10(3) 142-153

مصطلحات موضوعية: Continuous subcutaneous insulin infusion, multiple daily injections of insulin, quality of life

الوصف: Introduction: Diabetes mellitus is a serious condition, which can be life threatening if left untreated. It is well known that both types of diabetes, when not adequately controlled, are associated with various complications and poor quality of life. In type I diabetes mellitus, treatment is primarily performed by insulin administration. The various treatment regimens are aiming at optimally controlling sugar levels, preventing complications, facilitating patients' daily lives and improving their quality of life. Aim: The aim of the present study was to compare insulin administration with a continuous subcutaneous infusion or pump (CSII), to multiple daily insulin injections (MDI), regarding their efficacy in achieving normoglycemia and also improving quality of life, in patients with type I diabetes mellitus. Method: The methodology of this study was a literature review of the last 10 years, and was carried out in Pubmed's international database, by using keywords such as: Multiple Daily Insulin Injections, Quality of Life, Continuous Subcutaneous Insulin Infusion. Results: A total of 103 studies were found, of which 10 were used. 7 studies concluded that the pump improves patients' quality of life and achieves better glycemic control over the regimen (MDI). In contrast, 1 study showed a generally poor quality of life, although patients were satisfied with the pump use, while 1 study emphasized that good glucose values could be maintained with the regimen (MDI). Finally, 1 study found no significant differences in patients' quality of life between the two groups. Conclusions: It seems that continuous infusion of pumped insulin is a more ideal choice for achieving good glucose levels, thereby improving the quality of life in patients with type I diabetes, compared to the multiple insulin injections regimen.

العلاقة: https://zenodo.org/record/5842114Test; https://doi.org/10.5281/zenodo.5842114Test; oai:zenodo.org:5842114

الإتاحة: https://doi.org/10.5281/zenodo.5842114Test
https://doi.org/10.5281/zenodo.5842113Test
https://zenodo.org/record/5842114Test

المؤلفون: Vallejo Mora, María Del Rosario, Carreira, Mónica, Anarte, María Teresa, Linares, Francisca, Olveira, Gabriel, González Romero, Stella

مصطلحات موضوعية: Bolus calculator, Hypoglycemia, Multiple daily injections of insulin, Psychology, Type 1 diabetes, Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Fear, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Young Adult

الوصف: In a previous study we demonstrated improvement in metabolic control and reduction in hypoglycemia in people with type 1 diabetes on multiple daily injections, after having used a bolus calculator for 4 months. To demonstrate whether (1) extending its use (2) or introducing it in the control group, previously subjected to treatment intensification, could further improve metabolic control and related psychological issues. After the previous clinical trial, in which the subjects were randomized either to treatment with the calculator or to control group for 4 months, both groups used the calculator during an additional 4-month period. In the previous control group, after using the device, HbA1c did not improve (7.86% ± 0.87% vs. 8.01% ± 0.93%, P 0.215), although a significant decrease in postprandial hypoglycemia was observed (2.3 ± 2 vs. 1.1 ± 1.2/2 weeks, P 0.002). In the group in which the treatment was extended from 4 to 8 months, HbA1c did not improve either (7.61 ± 0.58 vs. 7.73 ± 0.65, P 0.209); however this group had a greater perceived treatment satisfaction (12.03 ± 4.26 vs. 13.71 ± 3.75, P 0.007) and a significant decrease in fear of hypoglycemia (28.24 ± 8.18 basal vs. 25.66 ± 8.02 at 8 months, P 0.026). The extension in the use of the calculator or its introduction in a previously intensified control group did not improve metabolic control, although it did confirm a decrease in hypoglycemic episodes in the short term, while the extension of its use to 8 months was associated with a reduction in fear of hypoglycemia and greater treatment satisfaction.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/11285Test; PMC5563860; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563860/pdfTest

الإتاحة: https://doi.org/10.1089/dia.2017.0019Test
http://hdl.handle.net/10668/11285Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563860/pdfTest

المؤلفون: Vallejo Mora, María Del Rosario, Carreira, Mónica, Anarte, María Teresa, Linares, Francisca, Olveira, Gabriel, González Romero, Stella

مصطلحات موضوعية: Bolus calculator, Hypoglycemia, Multiple daily injections of insulin, Psychology, Type 1 diabetes, Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Fear, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Young Adult

الوصف: In a previous study we demonstrated improvement in metabolic control and reduction in hypoglycemia in people with type 1 diabetes on multiple daily injections, after having used a bolus calculator for 4 months. To demonstrate whether (1) extending its use (2) or introducing it in the control group, previously subjected to treatment intensification, could further improve metabolic control and related psychological issues. After the previous clinical trial, in which the subjects were randomized either to treatment with the calculator or to control group for 4 months, both groups used the calculator during an additional 4-month period. In the previous control group, after using the device, HbA1c did not improve (7.86% ± 0.87% vs. 8.01% ± 0.93%, P 0.215), although a significant decrease in postprandial hypoglycemia was observed (2.3 ± 2 vs. 1.1 ± 1.2/2 weeks, P 0.002). In the group in which the treatment was extended from 4 to 8 months, HbA1c did not improve either (7.61 ± 0.58 vs. 7.73 ± 0.65, P 0.209); however this group had a greater perceived treatment satisfaction (12.03 ± 4.26 vs. 13.71 ± 3.75, P 0.007) and a significant decrease in fear of hypoglycemia (28.24 ± 8.18 basal vs. 25.66 ± 8.02 at 8 months, P 0.026). The extension in the use of the calculator or its introduction in a previously intensified control group did not improve metabolic control, although it did confirm a decrease in hypoglycemic episodes in the short term, while the extension of its use to 8 months was associated with a reduction in fear of hypoglycemia and greater treatment satisfaction.

العلاقة: http://hdl.handle.net/10668/11285Test; http://hdl.handle.net/20.500.12105/17317Test; Diabetes technology & therapeutics

الإتاحة: https://doi.org/20.500.12105/17317Test
https://doi.org/10.1089/dia.2017.0019Test
http://hdl.handle.net/10668/11285Test
https://hdl.handle.net/20.500.12105/17317Test